Payment overview · 2025
General Payments
$191.53
9 reported records · 5 companies
Healthcare provider profile · identity verified
Marvi Miranda, M.D.
Allopathic & Osteopathic Physicians|General Practice · DELHI, CA · NPI 1609265602
Verified facts
What the public records show
CMS Open Payments records show Marvi Miranda, M.D. received $191.53 in general payments during 2025 across 9 reported records.
GlaxoSmithKline, LLC. accounted for 48.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $93.00 | 48.6% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.56 | 22.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $26.06 | 13.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.82 | 8.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.09 | 7.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $191.53 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $59.06 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $59.06 | 3 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $54.82 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.56 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $42.56 | 2 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $33.94 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $26.06 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $14.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 121 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
92 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
121 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 644 | 183 |
| Metformin Hcl | Metformin Hcl | 531 | 153 |
| Lisinopril | Lisinopril | 409 | 107 |
| Omeprazole | Omeprazole | 386 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 325 | 88 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 319 | 47 |
| Gabapentin | Gabapentin | 283 | 80 |
| Losartan Potassium | Losartan Potassium | 283 | 81 |
| Furosemide | Furosemide | 265 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 263 | 74 |
| Ibuprofen | Ibuprofen | 252 | 61 |
| Diclofenac Sodium | Diclofenac Sodium | 223 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 223 | 64 |
| Trazodone Hcl | Trazodone Hcl | 184 | 46 |
| Glimepiride | Glimepiride | 181 | 52 |
| Baclofen | Baclofen | 180 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 177 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 160 | 52 |
| Alprazolam | Alprazolam | 138 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 130 | 24 |
| Meloxicam | Meloxicam | 124 | 30 |
| Ozempic | Semaglutide | 121 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 115 | 36 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 114 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 114 | 31 |
| Carvedilol | Carvedilol | 113 | 32 |
| Tramadol Hcl | Tramadol Hcl | 113 | 25 |
| Alendronate Sodium | Alendronate Sodium | 110 | 32 |
| Sertraline Hcl | Sertraline Hcl | 110 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 109 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 33 |
| Simvastatin | Simvastatin | 97 | 28 |
| Famotidine | Famotidine | 93 | 22 |
| Trulicity | Dulaglutide | 92 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 89 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 89 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 88 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 85 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 81 | 19 |
| Jardiance | Empagliflozin | 76 | 16 |
| Naproxen | Naproxen | 76 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 22 |
| Lorazepam | Lorazepam | 70 | 17 |
| Temazepam | Temazepam | 69 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 64 | suppressed |
| Celecoxib | Celecoxib | 62 | 15 |
| Clonazepam | Clonazepam | 62 | 16 |
| Atenolol | Atenolol | 61 | 13 |
| Azithromycin | Azithromycin | 59 | 50 |
| Enalapril Maleate | Enalapril Maleate | 56 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 16 |
| Eliquis | Apixaban | 52 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | suppressed |
| Mupirocin | Mupirocin | 51 | 26 |
| Allopurinol | Allopurinol | 50 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 50 | 17 |
| Potassium Chloride | Potassium Chloride | 49 | 13 |
| Finasteride | Finasteride | 48 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 48 | suppressed |
| Bupropion Xl | Bupropion Hcl | 47 | 11 |
| Montelukast Sodium | Montelukast Sodium | 46 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 12 |
| Spironolactone | Spironolactone | 45 | 12 |
| Glipizide | Glipizide | 44 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 15 |
| Propranolol Hcl | Propranolol Hcl | 42 | 14 |
| Fenofibrate | Fenofibrate | 41 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 11 |
| Meclizine Hcl | Meclizine Hcl | 41 | 16 |
| Donepezil Hcl | Donepezil Hcl | 40 | 13 |
| Ketoconazole | Ketoconazole | 39 | 25 |
| Ondansetron Odt | Ondansetron | 39 | 21 |
| Lovastatin | Lovastatin | 38 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 11 |
| Divalproex Sodium | Divalproex Sodium | 36 | suppressed |
| Latanoprost | Latanoprost | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Bumetanide | Bumetanide | 32 | 11 |
| Risperidone | Risperidone | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | 12 |
| Diazepam | Diazepam | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 19 |
| Sildenafil Citrate | Sildenafil Citrate | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Ibu | Ibuprofen | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 12 |
| Clotrimazole | Clotrimazole | 20 | suppressed |
| Epinephrine | Epinephrine | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Prednisone | Prednisone | 17 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 11 |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
| Permethrin | Permethrin | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $191.53 · 9 records | GlaxoSmithKline, LLC. | AREXVY, BEXSERO, CAPVAXIVE, Cologuard Collection Kit, GARDASIL 9, MOUNJARO, Ozempic, PENMENVY, ROTATEQ, Rybelsus, SHINGRIX, VAXELIS, VAXNEUVANCE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error